Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas

Eliana Amato1,2, Andrea Mafficini1,2, Kenichi Hirabayashi1,3, Rita T Lawlor1,2, Matteo Fassan1, Caterina Vicentini1,2, Stefano Barbì1, Pietro Delfino1, Katarzyna Sikora1, Borislav Rusev1, Michele Simbolo1, Irene Esposito1, Davide Antonello1, Antonio Pea1, Elisabetta Sereni1, Maria Ballotta1, Laura Maggino1, Giovanni Marchegiani1, Nobuyuki Ohike2, Laura D Wood8, Roberto Salvia1, Günter Klöppel1, Giuseppe Zamboni1,9,10, Aldo Scarpa2,3,4,9 and Vincenzo Corbo1,3,10

1 ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy
2 Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy
3 Department of Pathology, Tokai University School of Medicine, Isehara, Japan
4 Institute of Pathology, Heinrich-Heine-University and University Hospital of Düsseldorf, Düsseldorf, Germany
5 Department of Surgery, General Surgery B, University of Verona, Verona, Italy
6 Section of Anatomic Pathology, Azienda Ospedaliera Rovigo, Rovigo, Italy
7 Department of Pathology and Laboratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan
8 Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
9 Department of Pathology, Technical University Munich, Munich, Germany
10 Division of Pathology, Sacro Cuore-Don Calabria Hospital, Negrar, Italy

Keywords: Solid pseudopapillary neoplasms; pancreas; hypoxia; epigenetic regulators; metastasis

Abstract

Solid pseudopapillary neoplasms (SPN) of the pancreas are rare, low-grade malignant neoplasms that metastasise to the liver or peritoneum in 10–15% of cases. They almost invariably present somatic activating mutations of CTNNB1. No comprehensive molecular characterisation of metastatic disease has been conducted to date. We performed whole-exome sequencing and copy-number variation (CNV) analysis of 10 primary SPN and comparative sequencing of five matched primary/metastatic tumour specimens by high-coverage targeted sequencing of 409 genes. In addition to CTNNB1-activating mutations, we found inactivating mutations of epigenetic regulators (KDM6A, TET1, BAP1) associated with metastatic disease. Most of these alterations were shared between primary and metastatic lesions, suggesting that they occurred before dissemination. Differently from mutations, the majority of CNVs were not shared among lesions from the same patients and affected genes involved in metabolic and pro-proliferative pathways. Immunostaining of 27 SPNs showed that loss or reduction of KDM6A and BAP1 expression was significantly enriched in metastatic SPNs. Consistent with an increased transcriptional response to hypoxia in pancreatic adenocarcinomas bearing KDM6A inactivation, we showed that mutation or reduced KDM6A expression in SPNs is associated with increased expression of the HIF1α-regulated protein GLUT1 at both primary and metastatic sites. Our results suggest that BAP1 and KDM6A function is a barrier to the development of metastasis in a subset of SPNs, which might open novel avenues for the treatment of this disease.

© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Keywords: Solid pseudopapillary neoplasms; pancreas; hypoxia; epigenetic regulators; metastasis

Introduction

Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare low-grade malignant neoplasm that usually occurs in young women [1]. Histologically, SPN is composed by polygonal cells that form a solid and pseudopapillary pattern, where they become discohesive. SPN has a peculiar immunophenotype among primary pancreatic neoplasms, which encompasses the expression of the mesenchymal marker vimentin, the
protease inhibitor α1-anti-trypsin, the neuroendocrine marker neuron-specific enolase [1], progesterone receptors, CD10, CD56, cyclin D1 and claudins 5 and 7 [2]. There may be some variable expression of synaptophysin and focal, faint positivity for cytokeratins [1].

The majority of SPNs are confined to the pancreas, with metastases to the liver and peritoneum in up to 15% of cases [1]. SPN has an indolent clinical behaviour even for cases of large tumour size, and long-term prognosis following surgical resection is generally excellent for both localised and distant disease [3].

Transcriptional activation of the WNT signalling pathway through the oncogenic mutation of CTNNB1 (β-catenin gene) is the major driver of SPN tumorigenesis [1]. Mutations of CTNNB1 clustering into exon 3 of the gene prevent degradation of the encoded protein β-catenin, which accumulates in the nucleus to form transcriptionally active complexes with the DNA-binding proteins TCF and LEF1 [4].

In keeping with this, abnormal cytoplasmic and nuclear β-catenin accumulation is evidenced by immunohistochemistry (IHC) in virtually all SPNs [5]. In the nucleus, β-catenin activates transcription of CCND1 that is overexpressed in about 70% of SPNs [6]. Whole-exome sequencing (WES) of eight primary SPNs confirmed that they have nearly universal mutation of CTNNB1 and demonstrated that these tumours have a low mutational burden and infrequent copy-number changes compared with pancreatic adenocarcinoma [7].

Given that no molecular characterisation of metastatic SPN has been conducted to date, the genetic determinants of progression and metastasis of this tumour type remain undetermined. In this study, we undertook a comprehensive molecular characterisation of 10 primary SPNs for mutations and copy-number variations (CNVs) of coding genes. In addition, we analysed five matched primary/metastatic lesions, performing high-coverage targeted sequencing (HCTS) of the relevant regions of 409 cancer-related genes to uncover genetic alterations involved in the progression of the disease.

Materials and methods

Human research ethical approvals

Ethics committee approval was obtained at the three institutions involved in the collection of SPN cases. ARC-Net, University of Verona, Italy: approval number 1885 from the Integrated University Hospital Trust Ethics Committee (Comitato Etico Azienda Ospedaliera Universitaria Integrita). Tokai University, Japan: The Research Ethics Committee of Tokai University School of Medicine, Japan: approval number 17R275. University of Munich, Germany: approval number 503/16s from the Research Ethics Committee of Technical University of Munich.

SPN cohort

A cohort of 27 treatment-naïve and surgically resected SPNs was included in this study; details of molecular analyses conducted on each case are reported in supplementary material, Supplementary materials and methods and Table S1.

All cases were classified according to World Health Organization 2010 criteria [1]. The sequencing cohort included 15 cases whose clinicopathological information is provided in Table 1, comprising 11 with fresh-frozen and four with formalin-fixed paraffin-embedded (FFPE) tissue available. Five of these SPNs were metastatic (one fresh-frozen and four FFPE) and their matched liver metastases were available.

Immunohistochemistry

The following primary antibodies were used according to described staining protocols: β-catenin (Sigma-Aldrich, Milan, Italy; clone 15B8, 1:400 dilution) [2], GLUT1 (Bio-Optica, Milan, Italy; clone RB-9052, 1:100 dilution) [8], BAP1 (Santa Cruz Biotechnology, Heidelberg, Germany; clone C-4, 1:100 dilution) [9], KDM6A (Cell Signalling Technology, Leiden, The Netherlands; clone D3Q1l, 1:200 dilution) [10], p53 (Novoceastra-Leica, Buccinasco, Milan, Italy; clone DO-7, 1:50 dilution) [11]. BTD immunostaining was performed using a polyclonal antibody (Thermo Fisher Scientific, Monza, Milan, Italy; PA5-28180, 1:500 dilution) and standard IHC procedures [12]; endothelial cells served as internal positive controls for this antigen. For β-catenin, sections were evaluated for the presence of nuclear, cytoplasmic and membranous staining. Abnormal β-catenin immunostaining was defined as nuclear accumulation of the protein. Membranous and cytoplasmic immunostaining was considered for GLUT1 [13]. Cytoplasmic staining was considered for BTD, whereas nuclear staining was evaluated for both KDM6A and BAP1. Immunostaining for BAP1 was defined as ‘negative’ or ‘positive’, without considering an intensity cut-off value, due to unambiguous absence or presence of nuclear staining; specimens were classified as heterogeneous when at least 25% of neoplastic cells showed no nuclear staining. A three-tier intensity score (1+, 2+, 3+) was used for KDM6A and GLUT1 to denote weak, moderate and strong staining intensity, respectively. In particular, ‘strong’ for GLUT1 was defined as the staining intensity observed in red blood cells, whereas ‘strong’ and ‘weak’ for KDM6A were defined as the staining intensity showed by islets or acinar cells from non-neoplastic pancreas, respectively. For data analysis, cases were classified as either ‘high’ or ‘low’ by combining intensity scores as follow: 0 and 1+ (low); 2+ and 3+ (high).

Sequencing analysis

WES was performed on 10 primary tumour/normal DNA pairs using the SOLID 4 platform (Thermo Fisher Scientific).
Table 1. Summary of clinicopathological characteristics of the 15 patients whose SPN were subjected to sequencing

| Case | Age at diagnosis (years) | Sex (M/F) | Tissue origin | Diagnosis | Size (cm) | Tumour necrosis* | Mitosis (10 HPF) | Ki67 index (%) | Vascular invasion* | Perineural invasion* | Adipose tissue infiltration* | Lymph nodes* | Pleomorphism* |
|------|--------------------------|-----------|---------------|-----------|-----------|------------------|-----------------|----------------|------------------|-------------------|------------------------|-------------|--------------|
| Non-metastatic tumours | | | | | | | | | | | | |
| SPN1 | 32 | F | Pancreas | SPN | 9 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Light atypia† |
| SPN2 | 25 | F | Pancreas | SPN | 8 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| SPN3 | 50 | F | Pancreas | SPN | 3 | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| SPN4 | 40 | F | Pancreas | SPN | 5 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| SPN5 | 17 | M | Pancreas | SPN | 3.5 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| SPN6 | 43 | F | Pancreas | SPN | 4.5 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| SPN7 | 21 | F | Pancreas | SPN | 3 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| SPN8 | 12 | F | Pancreas | SPN | 14 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| SPN9 | 17 | F | Pancreas | SPN | 7 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| SPN10 | 24 | F | Pancreas | SPN | 5 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Metastatic tumours | | | | | | | | | | | | |
| SPN11 | 37 | F | Pancreas | SPN | 5 | — | — | — | 0 <1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| SPN11_L | 37 | F | Liver | Metastasis of SPN | 6 | Multiple | Synchronous | 0 <1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
| SPN12 | 14 | F | Pancreas | SPN | 9 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| SPN12_L | 14 | F | Liver | Metastasis of SPN | 1.3 | Solitary | 30 months | 0 <1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| SPN13 | 36 | F | Pancreas | SPN | 9 | — | — | — | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | |
| SPN13_La | 36 | F | Liver | Metastasis of SPN | 3.5 | Multiple | 9 months | 12 | 14 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| SPN13_Lb | 49.1 | F | Liver | Metastasis of SPN | 1.2 | — | — | — | 15 | 49.1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| SPN13_Lc | 1.8 | F | Liver | Metastasis of SPN | 1.2 | — | — | — | 20 | 74.8 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| SPN14 | 63 | F | Pancreas | SPN | 10 | — | — | — | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | |
| SPN14_La | 19.8 | F | Liver | Metastasis of SPN | 13 | Multiple | Synchronous and recurrence | 15 | 19.8 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | |
| SPN14_Lb | 17.6 | F | Liver | Metastasis of SPN | 13 | Multiple | Synchronous and recurrence | 15 | 19.8 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | |
| SPN56 | 23 | F | Pancreas | SPN | 8.5 | — | — | — | 0 <3 | 1 | 0 | 1 | 0 | 1 | 1 | |
| SPN56_L | 1.5 | F | Liver | Metastasis of SPN | 1.5 | Multiple | Synchronous | 6 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |

Blank fields, not evaluable.

*0, absent; 1, present.
†Defined as the presence of mild hyperchromasia and increased nuclear grooves.
Results

The study workflow is illustrated in supplementary material, Figure S1. For sequencing analysis, 15 SPN cases were collected. Of these 15 cases, five had metastases to the liver that were also available for sequencing analysis. Clinicopathological characteristics of the SPNs of the sequencing cohort are provided in Table 1. IHC analyses were conducted on the specimens from the sequencing cohort and on 12 additional SPNs, comprising 10 non-metastatic and two metastatic cases (see supplementary material, Table S1). Matched tumour/normal DNA of 10 non-metastatic SPNs underwent WES and high-density SNP array (see supplementary material, Tables S2 and S3). Comparative lesion sequencing [16,17] was performed by WES on one metastatic case with a single metastasis to the liver (see supplementary material, Tables S2 and S3). HCTS of the relevant region of 409 cancer-related genes was performed on the above case and four additional matched primary/metastatic specimens (see supplementary material, Table S4).

Clinicopathological characteristics of primary and metastatic SPNs

Most primary tumours showed the classical SPN microscopic features characterised by a heterogeneous combination of solid and cystic components. The solid components consisted of pseudopapillae with vascular stalks and hyalinised stroma within tumour areas and were intermingled by cystic haemorrhagic areas (see supplementary material, Figure S2A,B). Two of the metastatic tumours showed a diffuse solid growth pattern with minimal supporting fibrovascular stroma (see supplementary material, Figure S2C). This microscopic appearance was also maintained in the metastatic disease. Both of these tumours showed morphological features of aggressive behaviour, including mitoses, increased nuclear to cytoplasmic ratio, nuclear hyperchromasia and mild cellular atypia. In one of these two cases (SPN13), one of three hepatic lesions also presented with a distinct morphological component having sarcomatoid/dedifferentiated aspects (see supplementary material, Figure S3).

Somatic mutations and copy-number changes in non-metastatic SPNs

WES was performed on 10 primary SPNs and achieved a mean coverage of 44× in the tumour and 34× in matched normal samples. Detailed coverage information and the percentage of targeted bases are reported in supplementary material, Table S1. Activating mutations of CTNNB1 were present in all SPNs and were the only non-synonymous coding mutations identified in our cohort (see supplementary material, Table S3). All 10 CTNNB1 mutations were 1-bp missense mutations affecting exon 3 of the gene, distributed as follows: three mutations at codon 32, three at codon 37, two at codon 33 and two at codon 41 (Figure 1A). The allele frequency of CTNNB1 mutations was in the range of 21–44% (see supplementary material, Table S3). Copy-number analysis revealed that all cases were diploid except for one tumour (SPN3) showing loss of heterozygosity (LOH) on chromosome 21 (Figure 1B). Beyond mutations of CTNNB1, no recurrent genetic events were found in non-metastatic SPNs.
Figure 1. Somatic alterations identified in 10 primary SPNs. (A) Somatic mutations in CTNNB1 are missense mutations that cluster into exon 3 of the gene. The first 60N-terminal amino acids are represented. (B) LOH at chromosome 21 in case SPN3. The analysis shows Illumina GoldenGate assay (Illumina) SNP Array data from matched tumour and non-malignant DNA, with ASCAT estimates of the genomic copy number of the two parental copies of each chromosome (arbitrarily coloured in red and green). The genomic copy number is shown along the y-axis, while the chromosomal copy number is shown along the x-axis. In SPN3, ASCAT estimated that one copy of chromosome 21 (the ‘green’ copy) is completely deleted (copy number 0), leading to LOH (black arrow).

Somatic mutations in metastatic SPN

To address whether alterations other than CTNNB1 mutations are associated with the metastasis of SPN, we performed WES of an index case (SPN11), for which frozen tissue of a liver metastatic lesion was also available. WES achieved coverage of 60× in the tumour, 71× in the metastatic lesion and 21× in the normal sample (see supplementary material, Table S2). A total of four and two non-synonymous mutations were found in the tumour and the metastatic sample, respectively (Figure 2A). Mutations in CTNNB1 (p.D32Y) and in the histones biotinylation gene BTD [18] (p.L297Q) were shared between tumour and metastasis, whereas mutations in the apyrase gene ENTPD4 (p.R340NfsTer14) and the translocase of outer mitochondrial membrane gene TOMM22 (p.V99I) were identified exclusively in the primary. Mutations in BTD and ENTPD4 were predicted to be deleterious for gene function, whereas mutation in TOMM22 (p.V99I) was predicted to be benign (see supplementary material, Table S3). To further confirm that progression of SPN is associated with accumulation of genetic alterations and to explore the clonal relationship between primaries and metastases, we performed HCTS of the relevant regions of 409 cancer-related genes in four additional primary/metastatic specimens for which only FFPE tissues were available. The index case was also included in this analysis, leading to a total of 13 specimens analysed (five primaries and eight metastatic lesions). HCTS yielded an average coverage of 100× for at least 70% of targeted bases in both neoplastic and non-neoplastic samples. In total, 27 mutations affecting eight genes, which included CTNNB1, KDM6A, BAP1, TET1, SMAD4, TP53, FLT1 and FGFR3 (Figure 2B), were identified. Almost all mutations were missense, except for frameshift deletions affecting the genes encoding for the deubiquitinating enzyme BAP1 and the tyrosine kinase receptor FGFR3 (see supplementary material, Table S4). Mutations identified through WES in the index case could not be confirmed by HCTS, as the affected genes (BTD, ENTPD4, TOMM22) were not available in the targeted panel. Germline mutations of BTD cause an autosomal recessive disorder that can lead to delayed neurological development [19]. However, the role of this gene in cancer as well as the expression of its protein product in normal and neoplastic pancreatic tissues are neglected to date. Therefore, we first assessed the expression of BTD by IHC and found no immunoreactivity in both normal pancreas and in the 27 SPNs analysed. BTD staining was instead prominent in endothelial cells and normal hepatocytes (see supplementary material, Figure S4A). We concluded that the mutation of BTD was probably a passenger event. A low allele frequency (4%) missense mutation of TP53 was identified through HCTS of the metastatic specimen from the index case. Consistently, p53 immunoreactivity in this case was limited to a few nuclei (see supplementary material, Figure S4B), whereas none of the other metastatic or non-metastatic specimens showed any immunostaining. In keeping with our observation, mutation of TP53 has been previously reported as a rare event in SPNs [11]. As expected for a founder mutation, CTNNB1 alterations were shared among primary and matched metastatic lesions. Additional events that were present in all samples from a given patient included KDM6A mutations in SPN13, TET1 mutations in SPN14 and FLT1 mutations in SPN56. Mutations present in one
Figure 2. Somatic alterations in metastatic SPNs of the pancreas. (A) Somatic mutations identified in primary tumour and matched metastatic lesion of the index case by WES analysis. (B) Somatic mutations identified in matched primary/metastatic samples by targeted sequencing. (C) Total somatic mutations are displayed per case, including alterations shared among all lesions (founder) and those detected in one or more but not all of the specimens for a given case (progressor). The number of individual metastatic lesion (m) sequenced per case is indicated. See supplementary material, Table S4 for details.

or more but not all specimens from a given patient, and as such defined as progressor mutations, affected BAP1 and SMAD4 in SPN13 and FGFR3 in SPN56. In particular, BAP1 mutation was detected in the primary tumour and only in one of the three liver lesions, whereas SMAD4 mutation was detected exclusively in one metastatic lesion but not in the primary tumour. These data suggest that the majority of mutations occur before metastatic spread as they are shared among the different lesions from a given patient (Figure 2C). However, the identification of lesion-specific mutations indicates that subclones emerged either independently at primary or at metastatic sites as a consequence of ongoing clonal evolution.

Copy-number changes in metastatic SPN

CNV analysis at the chromosomal level was feasible only for the index case (SPN11) using WES data (supplementary material, Table S3). LOH of chromosome 22 detected through BAF analysis in the primary tumour was shared by the matched metastatic sample (see supplementary material, Table S3). Gene-level CNV analysis of the five metastatic SPN cases was conducted using HCTS data and revealed alterations in all the specimens analysed (see supplementary material, Figure S5). Figure 3A shows the detail of CNV differences detected among the four lesions analysed for the case SPN13. Differently from mutations, many CNVs were not shared among different specimens from a given case, thereby suggesting that they were independently acquired in each lesion as contributors to the progression of the disease (Figure 3B). Pathway enrichment analysis of genes with losses and gains among the SPN cases (SPN11, SPN13, SPN14 and SPN56) showed that altered genes are involved in metabolic and pro-proliferative pathways, such as central carbon metabolism, Rap1, Ras, Pi3K/Akt, mTOR and focal adhesion, all of which are known to be involved in tumour progression [20–25] (see supplementary material, Tables S6A,B).

Inactivation of epigenetic regulators in metastatic SPNs

Two of the five metastatic cases in our cohort showed mutations that were predicted to inactivate genes involved in epigenetic regulation, namely BAP1, KDM6A and TET1. Mutations of BAP1 and KDM6A were concurrent in the primary and one metastatic lesion of case SPN13, and co-occurring mutations of these genes have already been reported in bladder cancer [26].

© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
**Figure 3.** Somatic copy-number changes in metastatic SPN of the pancreas. (A) The virtual karyotype view shows the location, proximity and copy-number status of altered genes in the most representative case (SPN13) with the primary and three matched metastatic lesions available. The colouring scheme of chromosomal bands is as follows: black and grey = Giemsa positive; light red = centromere; purple = variable region. Alterations are annotated according to the colour codes presented in the figure. P, primary SPN; L(a–c), liver metastases. (B) Total somatic alterations (genes affected by CNV) are displayed per case, including alterations shared among all lesions (founder) and those detected in one or more (but not all) of the specimens for a given case (progressor). The number of individual metastatic lesion (m) sequenced per case is indicated. See supplementary material, Figure S5 and Table S5 for details.

KDM6A (also known as UTX) is a core component of the ‘complex of proteins associated with SET1’ (COMPASS) [10,27] and it has been shown to require BAP1 for its recruitment at chromatin enhancers [28]. Inactivation of those genes has been reported to occur through different mechanisms, ranging from DNA methylation to complex DNA rearrangements [25,29], which can be missed by targeted DNA sequencing. IHC is a reliable method to assess the status of BAP1 [30], while IHC for KDM6A has been recently used to assess the status of KDM6A in PDAC [10]. Therefore, we expanded the analysis of BAP1 and KDM6A status to the entire cohort of 27 SPNs (20 primaries and seven metastatic cases) by performing IHC on FFPE tissues. BAP1 was expressed in both islets and exocrine pancreatic cells (see supplementary material, Figure S4C). The primary tumour and the matched liver metastasis of case SPN13 sharing a deleterious mutation of BAP1 featured heterogeneous and homogenously negative staining for the gene product, respectively. Conversely, the other two hepatic...
Expression of BAP1 and KDM6A in primary SPN of the pancreas and in liver metastases. (A) BAP1 expression was evaluated by immunostaining in primary tumour and matched metastatic lesions. BAP1mut denotes specimens bearing inactivating mutation of the gene, whereas wild type denotes specimens lacking detectable mutations. (B) Contingency table (left) and stacked bar graph (right) showing BAP1 staining intensity in non-metastatic and metastatic SPNs. Primary-m, primary metastatic tumour; Het, heterogeneous staining as defined in supplementary materials. Increase in alteration from primary to metastasis was determined by chi-squared test for trend; scale bar is 100 μm and inset magnification 600×. (C) Representative IHC images showing different staining intensity for KDM6A in SPNs. Scale bar is 100 μm and inset magnification 600×. (D) Contingency table (left) and stacked bar graph (right) showing KDM6A staining intensity in non-metastatic and metastatic SPNs. Abs, absent; Mod, moderate; Str, strong. Significance was determined by Fisher’s exact test.

Metastases from SPN13 presented a homogeneously positive staining consistent with the absence of BAP1 mutation (Figure 4A). BAP1 was always expressed in the 20 non-metastatic SPNs, whereas staining was heterogeneous in three metastatic SPNs (one primary tissue and two metastases) and uniformly negative in one metastatic lesion (Figure 4B, Table 2). An inverse correlation was observed between metastatic SPNs and BAP1 staining (Figure 4B). In agreement with a previous study [10], KDM6A was expressed in islets and presented a mosaic expression in exocrine pancreas (see supplementary material, Figure S4C). Specimens from the case SPN13 bearing a missense mutation of KDM6A showed moderate staining, suggesting that the genetic alteration, which occurred proximal to the enzymatic domain, should not affect protein expression, but rather its function (Table 2). Strong expression of KDM6A was only detected in non-metastatic SPNs (Figure 4C, Table 2), whereas staining was absent in one hepatic lesion from a metastatic SPN. Overall, there was a statistically significant inverse correlation between metastatic SPNs and KDM6A staining (Figure 4C).

Reduced expression of KDM6A is associated with upregulation of GLUT1 in SPN

Direct and indirect evidence suggests that KDM6A is sensitive to changes in oxygen levels within the cells.
Table 2. Summary of BAP1 and KDM6A IHC on SPNs of 27 patients

| Sample ID | Tissue origin | Diagnosis | IHC for BAP1 | IHC for KDM6A |
|-----------|---------------|-----------|--------------|---------------|
| Non-metastatic SPNs | | | | |
| SPN1 | Pancreas | SPN | P | NE |
| SPN2 | Pancreas | SPN | P | NE |
| SPN3 | Pancreas | SPN | P | NE |
| SPN4 | Pancreas | SPN | P | NE |
| SPN5 | Pancreas | SPN | P | 1 |
| SPN6 | Pancreas | SPN | P | 3 |
| SPN7 | Pancreas | SPN | P | 2 |
| SPN8 | Pancreas | SPN | P | 3 |
| SPN9 | Pancreas | SPN | P | NE |
| SPN10 | Pancreas | SPN | P | 3 |
| SPN11 | Pancreas | SPN | P | 3 |
| SPN12 | Pancreas | SPN | P | 3 |
| SPN13 | Pancreas | SPN | P | 3 |
| SPN14 | Pancreas | SPN | P | 3 |
| SPN15 | Pancreas | SPN | P | 3 |
| Metastatic SPNs | | | | |
| SPN11_L | Liver | Metastasis of SPN | P | 1 |
| SPN12 | Pancreas | SPN | H | 1 |
| SPN12_L | Liver | Metastasis of SPN | N | 2 |
| SPN13 | Pancreas | SPN | H | 2 |
| SPN13_La | Liver | Metastasis of SPN | P | 2 |
| SPN13_Lb | Liver | Metastasis of SPN | P | 2 |
| SPN13_Lc | Liver | Metastasis of SPN | N | 2 |
| SPN14 | Pancreas | SPN | P | 1 |
| SPN14_La | Liver | Metastasis of SPN | P | 1 |
| SPN14_Lb | Liver | Metastasis of SPN | P | 1 |
| SPN16 | Pancreas | SPN | H | 2 |
| SPN16_La | Liver | Metastasis of SPN | P | 1 |
| SPN16_Lb | Liver | Metastasis of SPN | P | 1 |
| SPN17 | Pancreas | SPN | P | 1 |
| SPN17_L | Liver | Metastasis of SPN | P | 2 |

P, positive nuclear staining in 100% of tumour cells; N, negative for nuclear staining in 100% of tumours cells; H, heterogeneous nuclear staining with at least 25% of negative tumour cells; NE, not evaluable due to the absence of a positive internal control. 0, no tumour nuclear staining; 1, weak tumour nuclear staining; 2, moderate tumour nuclear staining; 3, strong tumour nuclear staining.

[31]. Inactivation of KDM6A is enriched in aggressive tumours, including PDAC [32]. Interrogating the International Cancer Genome Consortium (ICGC) cohort, we found that a hypoxia transcriptional signature is enriched in PDAC characterised by KDM6A inactivation (see supplementary material, Figure S6A). Although mechanisms are not always shared among tumour types, we sought to investigate whether mutation or reduced expression of KDM6A was also associated with a hypoxic signature in SPNs. To identify a reliable marker of hypoxia linked to KDM6A status, we retrieved PDAC data from the ICGC and The Cancer Genome Atlas (TCGA) databases and found that in both cohorts the hypoxia-related gene SCL2A1 (encoding for GLUT1) was significantly upregulated when KDM6A was inactive (see supplementary material, Figure S6B,C). Based on this information, we immunostained 18 samples from our cohort for GLUT1. GLUT1 expression was strongly upregulated in KDM6A-mutated tumours (both primary and metastatic) compared with KDM6A-proficient tumours (Figure 5A). Moreover, we found a trend to increased expression of GLUT1 in advanced SPNs ($p = 0.1$) and an inverse correlation between GLUT1 and KDM6A staining ($p = 0.003$, Figure 5B).

Discussion

Here we describe for the first time the genetic events associated with progression and metastasis of SPN. In keeping with previous reports [4,5,7], we showed that activating mutation of CTNNB1 is a universal feature of primary SPN and that no other recurrent alteration that affects protein-coding genes could be identified. Moreover, we found that clinically benign SPNs have diploid genomes and no relevant CNV, whereas one case with features of malignancy, including cellular atypia and high proliferative index associated with necrosis, showed LOH on chromosome 21. Overall, our data suggest that transcriptional activation of the WNT pathway is sufficient to drive tumourgenesis of SPN. Metastasis is the most common cause of cancer-related death.
Although metastasis can occur in up to 15% of SPN patients [1], only a few patients harbouring an undifferentiated carcinoma component have died of a metastatising SPN [34]. How cancer cells acquire the ability to colonise distant organs remains an unsolved question for SPN, mainly due to the paucity of metastatic specimens for molecular analyses. We used HCTS to analyse the clonal relationship between primary and hepatic lesions in five patients and found that the majority of mutations were shared among primaries and metastases, thereby suggesting that these events precede dissemination of cancer cells. Differently from mutations, the majority of CNVs were not shared among primaries and metastases. Although the reasons for this difference are difficult to infer from our data, we can speculate that differences in gene dosage reflect the selective pressure exerted by the different microenvironments or that subclones exist within primary tumours that could not be identified by our approach. Pathway enrichment analysis of genes within primary tumours that could not be identified by the different microenvironments or that subclones exist in gene dosage reflect the selective pressure exerted by 'squamous-like' transcriptional programmes, including response to hypoxia [38]. In keeping with this, our interrogation of ICGC and TCGA databases revealed that a hypoxia transcriptional signature is upregulated in PDAC tumours with inactivation of KDM6A. We explored this signature and identified GLUT1 as a biomarker that links hypoxia to KDM6A status in PDAC, and leveraged this information to verify if similar mechanisms were operating in SPNs. Although expression of GLUT1 did not significantly discriminate between metastatic and non-metastatic SPNs, we show here that tumours bearing inactivation of KDM6A or showing reduced protein expression strongly upregulate the expression of the hypoxia-marker GLUT1 in both primary and metastatic tissues. Although tumour hypoxia is strongly associated with cancer progression and resistance to therapy, we cannot conclude whether in SPN mutation or reduced expression of KDM6A is an epiphenomenon of oxygen shortage or instead precedes the formation of a hypoxic microenvironment.

Despite our sequencing cohort representing the largest analysed to date, we could not identify recurrent genetic alterations in metastatic SPNs. This may be due to either the number of cases analysed or the targeted sequencing approach, which have possibly precluded us from identifying common drivers of SPN progression. Nevertheless, this study provides the most comprehensive description, to date, of the molecular events that characterise the progression of malignancy in SPN and indicates alterations of BAP1 and KDM6A as potential drivers of metastasis in SPNs. This might have important therapeutic implication as, in other tumour types, BAP1 loss and reduced expression of KDM6A have been shown to drive malignancy through epigenetic alterations that can be pharmacologically reverted [28]. Although we have provided evidence that mechanisms can be shared between different malignancies, it remains to be determined whether BAP1 and KDM6A alterations are promoting tumour growth in SPNs through a similar epigenetic mechanism. In the absence of preclinical
models, this might only happen through multidimensional tumour profiling that will necessarily involve the integration of genetic and epigenetic analyses of a larger cohort of SPNs.

Acknowledgements

The study was supported by the Italian Cancer Genome Project (grant no. FIRB RBAP10AHJB), Associazione Italiana Ricerca Cancro (AIRC; grant no. 12182 to AS and 18178 to VC), FP7 European Community Grant (Cam-Pac No 602783). PD is supported by Fondazione Nadia Valsecchi. The funding agencies had no role in the collection, analysis and interpretation of data or in the writing of the manuscript.

Author contributions statement

AS, VC and GZ conceived the study. EA, AM, KH and RTL designed the study. EA, MS and DA designed the validation experiment. MF supervised the validation experiment. RTL co-ordinated patients and sample data management and supervised ethical protocols. AP, LM, GM, ES, RS, MB, NO, IE and GK collected materials and clinical data. GZ, MF, BR, GK, MB, IE and AS analysed histopathological data. EA, SB, KS, DA and AM carried out deep sequencing and raw data analysis. AM, PD and SB performed bioinformatic analysis. MF, CV and VC analysed IHC. VC, EA, AM and MF drafted the manuscript. GK, RTL and LDW revised the manuscript. VC and AS finalised the paper. All authors approved the submitted version.

References

1. Kloppel G, Hruban RH, Klimstra DS, et al. Solid-pseudopapillary neoplasm of the pancreas. In WHO Classification of Tumors of the Digestive System (4th edn), Bosman FT, Carneiro F, Hruban RH, et al. (eds). Lyon: IARC; 2010: 327–330.
2. Comper F, Antonello D, Beghelli S, et al. Expression pattern of claudins 5 and 7 distinguishes solid-pseudopapillary from pancreaticoblastoma, acinar cell and endocrine tumors of the pancreas. Am J Surg Pathol 2009; 33: 768–774.
3. Marchegiani G, Andrianello S, Massignani M, et al. Solid pseudopapillary tumors of the pancreas: specific pathological features predict the likelihood of postoperative recurrence. J Surg Oncol 2016; 114: 597–601.
4. Aoki M, Hecht A, Kruse U, et al. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci U S A 1999; 96: 139–144.
5. Tanaka Y, Kato K, Notohara K, et al. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res 2001; 61: 8401–8404.
6. Tietmann K, Heitling U, Kosmahl M, et al. Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q. Mod Pathol 2007; 20: 955–960.
7. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 2011; 108: 21188–21193.
8. Pertega-Gomes N, Felishino S, Massie CE, et al. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. J Pathol 2015; 236: 517–530.
9. Carbone M, Ferris LK, Baumann F, et al. BAPI cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MABATs. J Transl Med 2012; 10: 179.
10. Andricovich J, Perkail S, Kai Y, et al. Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. Cancer Cell 2018; 33: 512–526 e518.
11. Kim SA, Kim MS, Kim MS, et al. Pleomorphic solid pseudopapillary neoplasm of the pancreas: degenerative change rather than high-grade malignant potential. Hum Pathol 2014; 45: 166–174.
12. Simbolo M, Vicentini C, Ruzzeneente A, et al. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep 2018; 8: 7119.
13. Blayney JK, Cairns L, Li G, et al. Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. Oncotarget 2018; 9: 18518–18528.
14. Van Loo P, Nordgard SH, Lingjaerde OC, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 2010; 107: 16910–16915.
15. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 2013; 14: 7.
16. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114–1117.
17. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109–1113.
18. Kobza K, Camporeale G, Ruckert B, et al. K4, K9 and K18 in human histone H3 are targets for biotinylate by biotinidase. FEBS J 2005; 272: 4249–4259.
19. Hymes J, Stanley CM, Wolf B. Mutations in BTD causing biotinidase deficiency. Hum Mutat 2001; 18: 375–381.
20. Wong TL, Che N, Ma S. Reprogramming of central carbon metabolism in cancer stem cells. Biochim Biophys Acta 2017; 1866: 1728–1738.
21. Huang M, Anand S, Murphy EA, et al. EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene 2012; 31: 2783–2793.
22. di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013; 144: 1220–1229.
23. Ebrahimi S, Hosseini M, Shahidsales S, et al. Targeting the Akt/P73K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer. Curr Med Chem 2017; 24: 1321–1331.
24. Briest F, Grabowski P. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastrointestinalpancreatic neuroendocrine neoplasms. Theranostics 2014; 4: 336–365.
25. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495–501.
26. Nickerson ML, Dancik GM, Im KM, et al. Concurrent alterations in TERT, KDM6A, and the BRCA1 pathway in bladder cancer. Clin Cancer Res 2014; 20: 4935–4948.
27. Gozdecka M, Meduri E, Mazan M, et al. UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. *Nat Genet* 2018; 50: 883–894.

28. Wang L, Zhao Z, Ozark PA, et al. Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy. *Nat Med* 2018; 24: 758–769.

29. Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. *Cancer Cell* 2018; 33: 151.

30. Koopmans AE, Verdijk RM, Brouwer RW, et al. *Nat Genet* 2018; 50: 1410–1413.

31. Xia X, Lemieux ME, Li W, et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. *Proc Natl Acad Sci U S A* 2009; 106: 4260–4265.

32. Ezponda T, Dupere-Richer D, Will CM, et al. Loss of Polycomb and COMPASS function at enhancers for cancer therapy. *Proc Natl Acad Sci U S A* 2010; 107: 1297–1302.

33. Mehlen P, Puisieux A. Metastasis: a question of life or death. *Nat Rev Cancer* 2006; 6: 449–458.

34. Tang LH, Aydin H, Brennan MF, et al. The nuclear deubiquitinase UTX-mediated enhancer loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition. *Cell Rep* 2017; 21: 628–640.

35. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. *Nat Genet* 2011; 43: 668–672.

36. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science* 2010; 330: 1410–1413.

37. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nat Genet* 2013; 45: 1470–1473.

38. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016; 531: 47.

39. Li H, Durbin R. Fast and accurate long-read alignment with Burrows–Wheeler transform. *Bioinformatics* 2010; 26: 589–595.

40. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010; 20: 1297–1303.

41. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol* 2013; 31: 213–219.

42. Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014; 46: 310–315.

43. McLaren W, Pritchard B, Riis D, et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. *Bioinformatics* 2010; 26: 2069–2070.

44. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. *Nat Biotechnol* 2011; 29: 24–26.

45. Cingolani P, Patel VM, Coon M, et al. Using *Drosophila melanogaster* as a model for genotoxic chemical mutational studies with a new program, SnpSift. *Front Genet* 2012; 3: 35.

46. Reimand J, Arak T, Adler P, et al. Deriving functional interpretation of gene lists (2016 update). *Nucleic Acids Res* 2016; 44: W83–W89.

*Cited only in supplementary material.*

**SUPPLEMENTARY MATERIAL ONLINE**

**Supplementary materials and methods**

**Supplementary figure legends**

**Figure S1.** Flow charts of the sequencing analysis conducted on 154 SPN cases

**Figure S2.** Histological appearance of SPNs

**Figure S3.** Histological characteristics of metastatic SPN

**Figure S4.** IHC staining for BTD, TP53, KDM6A and BAP1

**Figure S5.** Detail of gene-level somatic copy-number changes in five metastatic SPNs of the pancreas

**Figure S6.** SLC2A1 expression is upregulated in PDAC bearing alterations of KDM6A

**Table S1.** Details of molecular analyses conducted on 27 SPNs

**Table S2.** WES summary data for 11 SPN cases

**Table S3.** Somatic alterations identified in 11 SPN specimens by WES and SNP array analysis

**Table S4.** Somatic alterations identified in matched tumour/metastatic specimens by targeted sequencing of 409 genes

**Table S5.** Somatic gene copy-number alterations identified in matched tumour/metastatic specimens by targeted sequencing of 409 genes

**Table S6A.** Enrichment analysis of main altered pathways according to copy-number alterations in four metastatic SPNs

**Table S6B.** Detailed list of genes in main affected pathways according to copy-number alterations analysis in four metastatic SPNs